Phil Pharma Wealth, Inc.

Phil Pharma Wealth, Inc. is a 100% Filipino-owned pharmaceutical company established on February 10, 1993, in response to the Philippine government's Generics Act of 1988, which aimed to provide affordable and quality medicines to the public. The company is headquartered at Suite 3001, 30th Floor, Tektite East Tower, Ortigas Center, Pasig City, Metro Manila. Phil Pharma Wealth, Inc. is licensed by the Securities and Exchange Commission and the Food and Drug Administration (FDA) of the Philippines to import and distribute a wide range of medical products, including finished pharmaceutical formulations such as tablets, capsules, syrups, injections, and medical devices. (philjobnet.gov.ph)

Over the years, the company has expanded its product portfolio to include over 300 items, with a particular focus on life-saving injectable products. This strategic emphasis aligns with the company's mission to enhance healthcare access across the Philippines by providing a one-stop solution for pharmaceutical needs, underpinned by a deep commitment to quality, affordability, and service excellence.

Phil Pharma Wealth, Inc. operates a centralized distribution model from its headquarters in Pasig City, Metro Manila. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's extensive product portfolio and focus on timely deliveries suggest a well-established distribution network capable of serving pharmacies, hospitals, and healthcare facilities throughout the Philippines. The company's strategic location in Metro Manila positions it advantageously to manage and distribute pharmaceutical products efficiently across the archipelago.

Phil Pharma Wealth, Inc. functions primarily as a pharmaceutical importer and wholesaler within the Philippine healthcare supply chain. By importing a diverse range of finished pharmaceutical formulations, including life-saving injectables, the company plays a crucial role in ensuring the availability of essential medicines across the country. Its focus on high-quality, affordable products positions it as a key player in the wholesale pharmaceutical market, catering to the needs of various healthcare providers.

Phil Pharma Wealth, Inc. demonstrates a high degree of supplier concentration, sourcing all its pharmaceutical products from a single supplier: Karnataka Antibiotics and Pharmaceuticals Limited (KAPL) in India. This exclusive sourcing strategy has resulted in a total import value of $238,000 USD over 19 shipments, with the top two products—Amikacin and Benzylpenicillin—accounting for 100% of the import value. While this concentration may offer benefits such as streamlined procurement processes and potentially favorable pricing, it also exposes the company to risks associated with supply chain disruptions, regulatory changes, or quality issues from the sole supplier. The absence of alternative suppliers could impact the company's ability to maintain a consistent supply of critical pharmaceutical products.

The resilience of Phil Pharma Wealth, Inc.'s supply chain is closely tied to its exclusive relationship with Karnataka Antibiotics and Pharmaceuticals Limited (KAPL). The lack of backup suppliers and the concentration on a limited number of formulations may pose challenges in the event of supply disruptions, regulatory changes, or quality control issues with KAPL. Additionally, the company's reliance on a single supplier for all its imports may limit its ability to diversify its product offerings or respond flexibly to changing market demands. To enhance supply chain resilience, it would be prudent for Phil Pharma Wealth, Inc. to consider establishing relationships with additional suppliers and diversifying its product portfolio.

Phil Pharma Wealth, Inc.'s sourcing pattern, characterized by exclusive reliance on Karnataka Antibiotics and Pharmaceuticals Limited (KAPL), has significant strategic implications. While this approach may have been effective in ensuring product consistency and potentially favorable pricing, it also exposes the company to risks associated with supply chain disruptions and regulatory changes affecting the sole supplier. For Indian exporters, this presents an opportunity to engage with Phil Pharma Wealth, Inc. by offering alternative products or formulations that could diversify the company's portfolio and reduce dependency on a single supplier. Establishing such partnerships could enhance the resilience and competitiveness of both parties in the Philippine pharmaceutical market.

The Food and Drug Administration (FDA) of the Philippines is the primary regulatory authority overseeing the importation, registration, and distribution of pharmaceutical products in the country. The FDA operates under the Department of Health and is responsible for ensuring the safety, efficacy, and quality of health products. Key legislation governing pharmaceutical imports includes the Food, Drug, and Cosmetic Act (Republic Act No. 3720), as amended by the FDA Act of 2009 (Republic Act No. 9711), which provides the legal framework for the regulation of health products in the Philippines.

Importers of pharmaceutical products in the Philippines must obtain a License to Operate (LTO) from the FDA, which authorizes them to import and distribute health products. Additionally, pharmaceutical products intended for importation must be registered with the FDA, ensuring they meet the required safety, efficacy, and quality standards. The FDA recognizes Good Manufacturing Practice (GMP) certificates from reputable authorities, including the European Union (EU), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the importation of products manufactured under these standards.

Imported pharmaceutical products must comply with the FDA's quality control measures, including batch testing and stability requirements, to ensure their safety and efficacy. Labeling requirements stipulate that all drug products must be properly labeled in accordance with FDA regulations, which include specific information such as the product name, dosage form, strength, and usage instructions. The FDA also mandates that labeling be in English or Filipino, the official languages of the Philippines, to ensure clear communication with consumers and healthcare providers.

In August 2024, the Department of Health of the Philippines issued Administrative Order No. 2024-0012, outlining the regulations for registering pharmaceutical products and Active Pharmaceutical Ingredients (APIs) intended exclusively for export. This order establishes guidelines, requirements, and procedures for the registration process of export-only pharmaceutical products and APIs, aiming to streamline the export process and enhance the competitiveness of Philippine pharmaceutical products in the global market.

Phil Pharma Wealth, Inc. has strategically focused on importing life-saving injectable products, including cephalosporins, penicillins and derivatives, aminoglycosides, anesthetic agents, antipsychotic agents, bronchodilators, and uterine stimulants. This focus aligns with the company's mission to provide affordable and quality medicines, particularly in critical therapeutic areas, thereby addressing the healthcare needs of the Filipino population. The emphasis on injectables reflects the company's commitment to offering essential medicines that are vital for patient care and survival. (philjobnet.gov.ph)

Phil Pharma Wealth, Inc. primarily sources its pharmaceutical products from Karnataka Antibiotics and Pharmaceuticals Limited (KAPL) in India. This sourcing strategy involves importing finished pharmaceutical formulations, including injectables, which are then distributed within the Philippine market. The company's focus on sourcing from a single supplier may offer benefits such as streamlined procurement processes and potentially favorable pricing; however, it also exposes the company to risks associated with supply chain disruptions and regulatory changes affecting the sole supplier.

Based on its product mix, Phil Pharma Wealth, Inc. serves the wholesale distribution segment of the Philippine pharmaceutical market. By importing and distributing a diverse range of pharmaceutical products, including life-saving injectables, the company caters to the needs of pharmacies, hospitals, and healthcare facilities across the country. Its focus on affordability and quality positions it as a trusted supplier within the healthcare supply chain.

There is a realistic opportunity for new Indian suppliers to engage with Phil Pharma Wealth, Inc. by offering alternative products or formulations that could diversify the company's portfolio and reduce dependency on a single supplier. Establishing such partnerships could enhance the resilience and competitiveness of both parties in the Philippine pharmaceutical market. Additionally, Indian exporters can explore opportunities to supply products that align with the therapeutic areas emphasized by Phil Pharma Wealth, Inc., such as injectables and life-saving medications.

Indian exporters seeking to supply pharmaceutical products to Phil Pharma Wealth, Inc. and the Philippine market must ensure that their products are registered with the FDA of the Philippines and manufactured in compliance with recognized Good Manufacturing Practice (GMP) standards, such as those from the EU, WHO, or PIC/S. Additionally, exporters must obtain a License to Operate (LTO) from the FDA, which authorizes them to import and distribute health products within the Philippines. Compliance with these regulatory requirements is essential for successful market entry and distribution.

Indian exporters interested in supplying Phil Pharma Wealth, Inc. should initiate contact by providing detailed product information, including GMP certifications and FDA registration details